Trump Announces Landmark Pfizer Drug Deal and 'TrumpRx' Website

Historic Agreement Reached at White House

On Tuesday, September 30, 2025, President Donald Trump announced a significant agreement with pharmaceutical giant Pfizer aimed at lowering prescription drug costs for American consumers and bolstering domestic manufacturing. The announcement, made from the Oval Office at the White House, featured President Trump alongside Pfizer CEO Albert Bourla and other key administration officials, including Health and Human Services Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz. , , ,

The deal represents a culmination of the Trump administration's months-long push to address high drug prices in the United States, which have historically been higher than in other developed nations. , ,

Key Provisions of the Pfizer Deal

The agreement with Pfizer encompasses several critical components:

• Most-Favored-Nation (MFN) Pricing: Pfizer committed to offering 'most-favored-nation' pricing to Medicaid programs across the country. This means that the prices for Pfizer products sold to Medicaid will align with the lowest prices offered in other developed nations. This policy will also apply to newly launched drugs. , , , , ,
• Direct-to-Consumer Discounts: Pfizer agreed to provide substantial discounts on many of its popular medications for direct purchase by consumers. These discounts are expected to range from 50% to 100%, and in some cases, even more. , , Specific examples of anticipated discounts include:
  • Duavee (for menopause symptoms): approximately 85% discount ,
  • Eucrisa (for atopic dermatitis): 80% discount , ,
  • Xeljanz (for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis): 40% discount ,
  • Zavzpret (for migraines): 50% discount ,
• U.S. Manufacturing Investment: As part of the agreement, Pfizer pledged to invest $70 billion in U.S. manufacturing facilities, research, and development. This commitment is linked to a three-year grace period from potential tariffs on pharmaceutical imports, a measure the administration had previously threatened. , , , , , ,

President Trump hailed the agreement, stating, 'I can't tell you how big this is.' Pfizer CEO Albert Bourla echoed this sentiment, remarking, 'I think today we are turning the tide and we are reversing an unfair situation.'

Introduction of 'TrumpRx' Website

In conjunction with the Pfizer deal, the administration unveiled plans for a new direct-to-consumer website named 'TrumpRx.' This platform is designed to allow patients to purchase discounted prescription drugs directly. , , , , , While specific details on its full functionality were limited, it was reported that patients would be able to pay in cash for certain medications. , , Pfizer confirmed that its discounted drugs would be available through the TrumpRx platform, which is anticipated to go live in early 2026. , ,

Context and Future Outlook

The announcement follows President Trump's executive order in May, which gave drugmakers a 30-day window to voluntarily lower prices or face new government payment limits. , , Letters were subsequently sent to 17 pharmaceutical companies in July, urging them to adopt MFN pricing, with a deadline of September 29. , , The White House indicated that negotiations with other pharmaceutical companies are ongoing, with expectations for similar agreements to follow. ,

While the agreement aims to provide significant savings, particularly for Medicaid and direct-to-consumer purchases, analysts have raised questions about its broader impact on individuals covered by private insurance, Medicare, or existing Medicaid co-payment structures. , ,